Laparoscopic Surgical Management of Epithelial Ovarian Cancer Cagatay Taskiran, MD, Assoc. Prof. VKV American Hospital, Division of Gynecologic Oncology.

Slides:



Advertisements
Similar presentations
Minimally Invasive Surgery in Gynecologic Oncology
Advertisements

CRITICAL APPRAISAL ON AN ARTICLE ABOUT PROGNOSIS
Intraperitoneal therapy in ovarian cancer Edward L. Trimble, MD, MPH National Cancer Institute, USA.
Management of colorectal cancer with liver metastasis Dr. Vivian Lee Department of Surgery, UCH.
Endometrial Cancer Surgical Staging (Role of Lymphadenectomy) Karl Podratz MD PhD FACS.
SURGICAL APPROACH TO GYNAECOLOGICAL CANCERS
Treatment in Recurrent Cervical Cancer
Impact of Lymph-Node Metastatic Site in Patients with Thoracic Esophageal Cancer Edited by: Kunisaki C., Makino H., Kimura J., Oshima T., Fujii S., Takagawa.
Trials in gastric cancer surgery Presenter Dr Pankaj Kumar Garg Moderator Dr Sunil Kumar.
ANDREW NG PRINCE OF WALES HOSPITAL Role of primary chemoradiation in esophageal carcinoma.
Materials & Methods Prospective study in tertiary oncology centre. PJ used in 15 laparotomies and 6 laparoscopic debulking. Patient demographics, intra.
Management of early rectal carcinoma Joint Hospital Surgical Grand Round Jeren Lim United Christian Hospital.
Dr.Yousefi Gynecologist Oncologist Surgical Staging Conservative Surgery Cytoreduction Surgery Optimal Cytoreduction Intraperitoneal Chemotherapy Neoadjuvant.
Joint Hospital Surgical Grand Round 21 st July, 2012 RH.
The role of surgery in the management of mesothelioma Mr Martyn Carr Consultant Thoracic Surgeon Liverpool Heart and Chest Hospital.
A REVISIT TO MANAGEMENT OF GASTROINTESTINAL STROMAL TUMOUR (GIST) Joint Hospital Surgical Grand Round 17 Jan 2015 Grace Liu Pamela Youde Nethersole Eastern.
Lars Påhlman Dept. Surgery, Colorectal unit, University Hospital, Uppsala, Sweden How to handle peritoneal carcinomatosis found at laparotomy.
Neoadjuvant Chemotherapy or Primary Debulking Surgery in Advanced Ovarian Cancer Ignace Vergote, MD PhD University Hospitals Leuven, Belgium IGCS Santa.
Neoadjuvant Chemotherapy for Ca Breast CY Choi UCH.
Endometrial Carcinoma Fuat Demirkıran, MD Istanbul University, Cerrahpaşa School Of Medicine, OB&GYN Department, Gyn Oncology.
{ Upper Abdominal Debulking of Gynecologic Malignancies Shaun McKenzie, MD Assistant Professor of Surgery University of Kentucky.
4% of all female cancers 25% of all gynecologic cancers life time risk: 1/70 ¾ advanced stage most lethal Epithelial Ovarian Cancer:
Dpt. Obstetrics & Gynecology Catholic University - Rome
Primary Debulking for Bulky Advanced Stage Ovarian Cancer Ginger J. Gardner, MD Director, Survivorship Program Gynecology Service, Department of Surgery.
10 Minutes Talk 吳 華 席 Hua-Hsi Wu, MD OB/GYN, VGH-TPE Sep 08, 2008.
Lymphadenectomy in Epithelial Ovarian Cancer
Phase II Presurgical Feasibility Study of Bevacizumab in Untreated Patients with Metastatic Renal Cell Carcinoma Jonasch E et al. Journal of Clinical Oncology.
Laparoscopic Pancreatectomy Attila Nakeeb, M.D., F.A.C.S. Department of Surgery Indiana University School of Medicine 7th Annual Symposium on Gastrointestinal.
Laparoscopic Managment of Adnexal Mass Prof. Dr. Fuat Demirkıran I.U Cerrahpaşa School of Medicine. Department of OB&GYN Division Of Gynocol Oncol TJOD.
Laparoscopic Liver Resections David A. Kooby, MD, FACS Associate Professor of Surgery Division of Surgical Oncology Emory University School of Medicine.
Residents’ Journal Club Giao Q. Phan, M.D. September 4, 2014.
J. Lujan, G. Valero, Q. Hernandez, A. Sanchez, M.D. Frutos and P. Parrilla. British Journal of Surgery, September 2009.
Mamoun A. Rahman Surgical SHO Mr Osborne’s team. Introduction Blood transfusion: -Preoperative ( elective) -Intra/postoperative ( urgent) Blood transfusion.
Who can benefit from chemotherapy holidays after first-line therapy for advanced colorectal cancer ? N. Perez-Staub, B. Chibaudel, A. Figer, A. Cervantes,
Surgery As Monotherapy for Wilms’ Tumor Lisly Chéry April 15, 2010.
Relapsed/Refractory Ovarian Cancer: Decision Points in Diagnosis and New Treatment Strategies Friday, March 24, 2006 Palm Springs Convention Center Primrose.
HE-4 TRIAL Prospective phase II trial on the prognostic and predictive value of HE-4 regression during neoadjuvant chemotherapy for advanced ovarian, Fallopian.
D2 Lymphadenectomy Alone or with Para-aortic Nodal Dissection for Gastric Cancer NEJM July vol 359 R2 임규성.
David Cibula, VFN Innovation in surgical approach of ovarian cancer David Cibula Gynecologic Oncology Centre General Faculty Hospital in Prague.
Debulking in Ovarian Cancer Ashraf Fawzy Nabhan Assistant Prof. of Obstetrics & Gynecology Ain Shams University, Cairo, Egypt.
Neoadjuvant chemotherapy in the treatment of NSCLC Department of Thoracic Oncology, University Hospital Ghent, Belgium Current Opinion in Oncology 2007,
Case report Ovarian cancer Ami Fishman, M.D. Meir Hospital - Sapir Med Center Kfar-Saba, Israel Ovarian cancer Ami Fishman, M.D. Meir Hospital.
Management of Malignant Ovarian Germ Cell Tumors
Management of early stage cervical cancer
Shazia Bashir MD, MPH Gynecologic Oncologist
Primary Debulking vs NACT+IDS in EOC (PFS/OAS/Morbidity)
LION (Phase III Trial): Lymphadenectomy for LN-Negative Advanced Ovarian Cancer Following Complete Resection CCO Independent Conference Highlights* of.
FERTILITY SPARING IN OVARIAN CANCER
Adjuvant chemotherapy for early stage epithelial ovarian cancer
Gazi ABDULHAY, Sebile GÜLER ÇEKİÇ
Short-term outcome of neo-adjuvant chemotherapy
Laparoscopic Hysterectomy in Obese Women
Laparoscopic Surgery in Gynaecologic Oncology An Added Value?
Surgery for Ovarian Cancer: Progress and Future Directions
Figure #1 Overall survival Figure #2 Disease free survival
Previous abdominal surgery and obesity does not affect unfavorably the outcome of total laparoscopic hysterectomy Yavuz Emre ŞÜKÜR Ankara University School.
LaparoscopIc para-aortIc lymphadenectomy
Amant F – Gynecological Oncology - UZ Gasthuisberg, Leuven
THBT neoadjuvant endocrine therapy is to be used in post-menopausal breast cancer woman Antonino Grassadonia Università «G. D’Annunzio» – Chieti-Pescara.
OPTIMIZING TREATMENT FOR ADVANCED OVARIAN CANCER:
ROLE OF MIS IN EARLY STAGE OVARIAN CANCER
HEPATIC RESECTION FOR PARENCHIMATOUS OVARIAN CANCER LIVER METASTASES BEYOND SECONDARY CYTOREDUCTION FOR RELPASED OVARIAN CANCER Nicolae Bacalbasa1,
Laparoscopic Surgery in Gynaecologic Oncology
Tertiary cytoreductive surgery in recurrent epithelial ovarian cancer:
盧建璋, 陳鴻華, 李克釗, 胡萬祥, 張家駱, 蔡鎧隆, 林岳民, 鄭功全, 吳昆霖
ROBOTIC ASSISSTED RADICAL PROSTATECTOMY OUR INITIAL EXPERIENCE
Adjuvant Radiation is Required for Gastric Cancer
Effect of NACT on optimal debulking in advanced EOC-A retrospective study at a tertiary cancer centre Investigator: Dr.Rekha.B.R Fellow-gynec onco Guide:
Eung Chang Lee, Sung-Sik Han, Hyeong Min Park,
Presentation transcript:

Laparoscopic Surgical Management of Epithelial Ovarian Cancer Cagatay Taskiran, MD, Assoc. Prof. VKV American Hospital, Division of Gynecologic Oncology

L/S & EOC  Primary trt for early stage disease  Restaging  Primary cytored’n for advanced disease  Surgical trt for recurrent disease  To assess resectability: Neoadjuvant CT  VATS

Early Stage is Rare

 Comprehensive surgical staging Exploration - Cytology and biopsies Hyst-BSO- fertility sparing surgery PPLND- Total Omentectomy Appendectomy Standard Surgery for Early Stage Ovarian Cancer

Schuler et al, 1999, EJOGRB 401 patients, 24% up-staging  Diaphragma  Omentum  PPALN  Cytology Up-staging

Distribution of LN Metastasis

Early stage ovarian cancer & Laparoscopy  Retrospective series  Case-control studies  Meta-analysis  Cochrane review Literature

Early stage ovarian cancer & Laparoscopy 1994, Querleu-Leblanc 9 patients  Still small series, number low  11 studies, 9-42 pt, 88 multicenter  Approximately 400 patients Literature

Chi, AJOG, 2005, 50 pt LN number, omental size: no problem No conversion to L/T Survival rates similar Park, Ann Surg Oncol, 2008, 36 pt LN number, omental size: no problem Upstaging rate is same No recurrence within 20 months Comparative Studies & Feasibility

Whole Literature

Endometrial cancer – randomized studies EBL lower Shorter hospital stay Fewer postoperative complications Improved QOL Faster return to normal function Similar for ovarian cancer – no RCT, shorter interval to adjuvant chemotherapy Benefits of Laparoscopy

Ghezzi, 2 012, 88 pt Blood tx rate 2.8% vs 19.2% Postoperative complications 3.2% vs 31% Febrile morbidity Ileus Wound dehiscence Wound infection Benefits of Laparoscopy

Cost Complications Hospital stay Performance – return to work – CT ?? Improved fecundity after fertility sparing surgery - adhesions Potential Benefits & Some Conflicts

Rupture – IC – Chemo – survival is worsened  L/T 10% and L/S 15-20%  Size and endobag usage  Rupture vs puncture ?? Possible Risks & Rupture

11 studies EBL lower Upstaging rate 23% Conversion to L/T 3.7% Recurrence rate 9.9% (6.7-14) Intraop rupture 25% !!!!! Only 1 port site-metastasis Meta-Analysis & Accepted 4 April AJOG

Overall 12 hasta Borderline8 pt EOC4 pt (all restaging) LN number31-84 Omentectomyno problem No conversion No intra-postop comp Median time 5 hr Data

Trocar Sites

 >20 cases PLN number satisfactory, time shorter, complications decrease; LN number:  Paraaortic LN number increase by years: Transperitoneal LA & Learning curve Kohler, GO, 2004

Transperitoneal LA & Duration Kohler, GO, 2004

14 studies Re-staging & Up-staging

Timing of Restaging Lehner 1998 max. 15 days Kinderman 1996 max. 8 days Adequate staging is very important

Primary Debulking for Advanced Disease Fanning, 2011, GO  CT: omental metastasis – ascites  25 cases – 2 conversions: severe omental-RS  36% no residual  Hospiatal stay median 1 day  Blood loss 340 ml  Median OS: 3.5 years

Primary Debulking for Advanced Disease Nezhat, JSLS, 2010  28 pt, 11 open after diagnostic L/S  %88 optimal  Time and complication rates are same  Blood loss and hospital stay less  9 NED, 6 AWD, 2 DOD

Secondary Cytoreduction Magrina, 2013, GO,  L/S: 9, Robot:10, L/T:33 patients  15 types of different procedures  No conversion  No difference: Op. Time, comp’n, complete debulking, survival  Endoscopy: Blood loss and hospital stay  L/T: 3 major procedures, upper and lower quadrants

Secondary Cytoreduction Nezhat, JSLS, 2012, only L/S  , secondary 20, tertiary 3 cases  %82 optimal  200 min, 75 ml, stay 2 days  1 conversion  No intraop complication  NED:12  AWD:6  DOD:4  Median DFS: 72 months

Conclusion  There is limited data on the role laprascopic surgery for early stage ovarian cancer  Although it was started at nearly the same time periods with EC and CC it was not populirezed  It seems feasible for surgical procedures, upstaging rates, adequacy of lymphadenectomy and omentectomy  Survival rates are similar with laparotomy  Port site metastasis is rare, Major problem is tumor rupture

Conclusion  There is limited data on the value of laparoscopic surgery for recurrent disease. It seems feasible for highly selected patients at very experienced centers  It may be good way to assess resectability for advanced cases both before primary surgery and after NACT  VATS should be performed for patients having moderate to severe pleural effusion beforre abdominal cytoreduction

Thanks for your attention ….

The Effect of Cyst Rupture on Survival ImportantNot Important seriesnsriesn Gleeson NC23Sevelda P60 Lehner R70Kruitwagen RF219 Leminen A154Ahmed FY194 Vergote I1545Abu-Rustum NR289

 Steinberg, GO, 1986  Normally seen omentum: 22% involvement  Leblanc, Semin Surg Oncol, 2000  Clinical stage I 5 %  Ayhan, AJOG, 2007  Stage I-II 3.6% occult metastasis Up-staging & Omentum

Lymphatic Metastasis  Poor prognostic factor  Paraaortic LN metastasis is frequent  Lymph node size is not related with metastasis  Imaging is not sufficient

LN Metastasis at Stage I n #LN metastasis % Pickel H 2825 Burghardt E 3724 Bendetti-Panici P 3514 Petru E 40(44% ≤ 2mm) 23 Onda T 3321 Baiocchi G Faught W Pickel H, Baillieres Clin Obstet Gynaecol, 1989; Burghardt E, Gynecol Oncol, 1991; Bendetti-Panici P, Gynecol Oncol, 1993; Petru E, Am J Obstet Gynecol, 1994; Onda T, Cancer, 1996; Baiocchi G, Gynecol Oncol, 1998; Faught W, J Obstet Gynaecol Can, 2003

LN Metastasis & Laterality